Britain’s GlaxoSmithKline and France’s Sanofi on Monday said they had started a new clinical trial of their protein-based COVID-19 vaccine candidate and aim to reach the final testing stage in the second quarter.
The move comes after the drugmakers in December said their vaccine would be delayed after clinical trials showed an insufficient immune response in older people.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.